A Multicenter Retrospective Cohort Study Comparing Clinical and Economic Outcomes in Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)

Trial Profile

A Multicenter Retrospective Cohort Study Comparing Clinical and Economic Outcomes in Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Ceftaroline fosamil (Primary) ; Daptomycin
  • Indications Methicillin-resistant Staphylococcus aureus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2017 New trial record
    • 08 Oct 2017 Primary endpoint (Composite failure defined as 30-day mortality, BSI duration 7 days post-study drug initiation, or 60-day recurrence) has not been met, according to results presented at the IDWeek 2017.
    • 08 Oct 2017 Results presented at the IDWeek 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top